Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. It operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. It also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, the company provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. It provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Elevance Health Inc.

Electrovaya Inc. (($TSE:ELVA)) has held its Q4 earnings call. Read on for the main highlights of the call. Electrovaya Inc.’s recent earnings call ...

Electrovaya Inc. Reports Record Growth and Profitability

Electrovaya ( ($TSE:ELVA) ) has issued an announcement. Electrovaya Inc. announced its fiscal year 2025 results, marking its first profitable year ...

Electrovaya Achieves First Profitable Year with Record Revenue in FY 2025

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Indivior (INDV – Research Report) and Enliven Therap...

Analysts Offer Insights on Healthcare Companies: Indivior (INDV) and Enliven Therapeutics (ELVN)

There’s a lot to be optimistic about in the Industrial Goods sector as 3 analysts just weighed in on Electrovaya (ELVA – Research Report), RTX (RTX...

Analysts’ Top Industrial Goods Picks: Electrovaya (ELVA), RTX (RTX)

In a report released today, Austin Yun from Macquarie maintained a Buy rating on Elevra Lithium, with a price target of A$7.00. Yun covers the Basi...

Macquarie Sticks to Its Buy Rating for Elevra Lithium (SYAXF)

Elevra Lithium ( ($AU:ELV) ) has issued an announcement. Elevra Lithium Limited announced a change in the director’s interest, with Laurie Lefcourt...

Elevra Lithium Director Increases Stake in Company

An announcement from Electrovaya ( ($TSE:ELVA) ) is now available. Electrovaya Inc. announced that it will release its fourth quarter and fiscal ye...

Electrovaya to Announce Q4 and FY-2025 Financial Results

There’s a lot to be optimistic about in the Industrial Goods sector as 3 analysts just weighed in on Spire Global (SPIR – Research Report), Grupo A...

Analysts Offer Insights on Industrial Goods Companies: Spire Global (SPIR), Grupo Aeroportuario del Sureste (ASR) and Electrovaya (ELVA)

Electrovaya ( ($TSE:ELVA) ) has issued an update. Electrovaya Inc. announced significant business updates, including insider share purchases and pr...

Current Quarter	$3.2	Next Quarter	$10.65
Current Year	$30	Next Year	$27.61
QoQ Growth	+232.8%	YoY Growth	-8.0%
3Y EPS CAGR	N/A	Target Price	$384.95
Consensus	Buy	Upside	+7.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ELV	$359.07	-0.32%	2.09M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ELV	$359.07	-0.3%	2.09M
3
4
5
6

ELV

ELV

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Elevance Health Inc. Data in Excel

Get Elevance Health Inc. Data in Excel